vs
Side-by-side financial comparison of Dream Finders Homes, Inc. (DFH) and Hologic (HOLX). Click either name above to swap in a different company.
Dream Finders Homes, Inc. is the larger business by last-quarter revenue ($1.2B vs $1.0B, roughly 1.2× Hologic). Hologic runs the higher net margin — 17.1% vs 4.8%, a 12.2% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -22.3%). Hologic produced more free cash flow last quarter ($215.2M vs $136.0M). Over the past eight quarters, Dream Finders Homes, Inc.'s revenue compounded faster (21.0% CAGR vs 1.5%).
Dream Finders Homes, Inc. is a U.S. homebuilding firm that constructs and sells entry-level to luxury residential properties, including single-family homes and townhomes, across high-growth domestic markets. It also provides mortgage, title insurance and home warranty services for homebuyers.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
DFH vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.0B |
| Net Profit | $58.8M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 6.4% | 22.6% |
| Net Margin | 4.8% | 17.1% |
| Revenue YoY | -22.3% | 2.5% |
| Net Profit YoY | -54.9% | -10.9% |
| EPS (diluted) | $0.57 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $1.0B | ||
| Q3 25 | $969.8M | $1.0B | ||
| Q2 25 | $1.2B | $1.0B | ||
| Q1 25 | $989.9M | $1.0B | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.0B | $988.0M | ||
| Q2 24 | $1.1B | $1.0B | ||
| Q1 24 | $827.8M | $1.0B |
| Q4 25 | $58.8M | $179.1M | ||
| Q3 25 | $47.0M | $187.2M | ||
| Q2 25 | $56.6M | $194.9M | ||
| Q1 25 | $54.9M | $-17.4M | ||
| Q4 24 | $130.5M | $201.0M | ||
| Q3 24 | $70.7M | $178.6M | ||
| Q2 24 | $80.9M | $194.5M | ||
| Q1 24 | $54.5M | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | 19.2% | 55.4% | ||
| Q1 24 | 18.0% | 53.3% |
| Q4 25 | 6.4% | 22.6% | ||
| Q3 25 | 6.3% | 22.6% | ||
| Q2 25 | 6.4% | 24.9% | ||
| Q1 25 | 7.2% | -0.7% | ||
| Q4 24 | 10.8% | 22.5% | ||
| Q3 24 | 9.2% | 23.3% | ||
| Q2 24 | 10.0% | 24.1% | ||
| Q1 24 | 8.6% | 20.7% |
| Q4 25 | 4.8% | 17.1% | ||
| Q3 25 | 4.8% | 17.8% | ||
| Q2 25 | 4.9% | 19.0% | ||
| Q1 25 | 5.5% | -1.7% | ||
| Q4 24 | 8.4% | 19.7% | ||
| Q3 24 | 7.0% | 18.1% | ||
| Q2 24 | 7.7% | 19.2% | ||
| Q1 24 | 6.6% | 16.7% |
| Q4 25 | $0.57 | $0.79 | ||
| Q3 25 | $0.47 | $0.84 | ||
| Q2 25 | $0.56 | $0.86 | ||
| Q1 25 | $0.54 | $-0.08 | ||
| Q4 24 | $1.28 | $0.87 | ||
| Q3 24 | $0.70 | $0.75 | ||
| Q2 24 | $0.81 | $0.82 | ||
| Q1 24 | $0.55 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $234.8M | $2.4B |
| Total DebtLower is stronger | $1.6B | $2.5B |
| Stockholders' EquityBook value | $1.4B | $5.2B |
| Total Assets | $3.7B | $9.2B |
| Debt / EquityLower = less leverage | 1.13× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $234.8M | $2.4B | ||
| Q3 25 | $251.0M | $2.2B | ||
| Q2 25 | $210.3M | $1.9B | ||
| Q1 25 | $297.5M | $1.6B | ||
| Q4 24 | $274.4M | $2.0B | ||
| Q3 24 | $204.9M | $2.3B | ||
| Q2 24 | $274.8M | $2.4B | ||
| Q1 24 | $239.4M | $2.2B |
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.8B | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $1.3B | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | $1.4B | $5.2B | ||
| Q3 25 | $1.4B | $5.0B | ||
| Q2 25 | $1.3B | $4.8B | ||
| Q1 25 | $1.3B | $4.6B | ||
| Q4 24 | $1.2B | $4.8B | ||
| Q3 24 | $1.1B | $5.1B | ||
| Q2 24 | $1.0B | $5.0B | ||
| Q1 24 | $968.7M | $4.8B |
| Q4 25 | $3.7B | $9.2B | ||
| Q3 25 | $3.8B | $9.0B | ||
| Q2 25 | $3.7B | $8.8B | ||
| Q1 25 | $3.5B | $8.5B | ||
| Q4 24 | $3.3B | $8.7B | ||
| Q3 24 | $3.3B | $9.2B | ||
| Q2 24 | $3.0B | $8.9B | ||
| Q1 24 | $2.7B | $8.7B |
| Q4 25 | 1.13× | 0.48× | ||
| Q3 25 | 1.29× | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | 1.03× | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $143.6M | $229.9M |
| Free Cash FlowOCF − Capex | $136.0M | $215.2M |
| FCF MarginFCF / Revenue | 11.2% | 20.5% |
| Capex IntensityCapex / Revenue | 0.6% | 1.4% |
| Cash ConversionOCF / Net Profit | 2.44× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $-126.4M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $143.6M | $229.9M | ||
| Q3 25 | $-131.0M | $355.1M | ||
| Q2 25 | $-68.5M | $343.3M | ||
| Q1 25 | $-44.7M | $169.4M | ||
| Q4 24 | $306.5M | $189.3M | ||
| Q3 24 | $-205.0M | $367.0M | ||
| Q2 24 | $-110.6M | $405.8M | ||
| Q1 24 | $-247.5M | $292.4M |
| Q4 25 | $136.0M | $215.2M | ||
| Q3 25 | $-135.7M | $341.4M | ||
| Q2 25 | $-78.8M | $330.5M | ||
| Q1 25 | $-47.9M | $153.9M | ||
| Q4 24 | $302.6M | $172.5M | ||
| Q3 24 | $-222.5M | $350.6M | ||
| Q2 24 | $-112.4M | $385.3M | ||
| Q1 24 | $-249.6M | $279.6M |
| Q4 25 | 11.2% | 20.5% | ||
| Q3 25 | -14.0% | 32.5% | ||
| Q2 25 | -6.8% | 32.3% | ||
| Q1 25 | -4.8% | 15.3% | ||
| Q4 24 | 19.4% | 16.9% | ||
| Q3 24 | -22.1% | 35.5% | ||
| Q2 24 | -10.6% | 38.1% | ||
| Q1 24 | -30.2% | 27.5% |
| Q4 25 | 0.6% | 1.4% | ||
| Q3 25 | 0.5% | 1.3% | ||
| Q2 25 | 0.9% | 1.3% | ||
| Q1 25 | 0.3% | 1.5% | ||
| Q4 24 | 0.3% | 1.6% | ||
| Q3 24 | 1.7% | 1.7% | ||
| Q2 24 | 0.2% | 2.0% | ||
| Q1 24 | 0.3% | 1.3% |
| Q4 25 | 2.44× | 1.28× | ||
| Q3 25 | -2.79× | 1.90× | ||
| Q2 25 | -1.21× | 1.76× | ||
| Q1 25 | -0.81× | — | ||
| Q4 24 | 2.35× | 0.94× | ||
| Q3 24 | -2.90× | 2.05× | ||
| Q2 24 | -1.37× | 2.09× | ||
| Q1 24 | -4.54× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DFH
| Midwest Segment | $454.2M | 37% |
| Southeast Segment | $397.5M | 33% |
| Mid Atlantic Segment | $307.3M | 25% |
| Financial Services Segment | $53.7M | 4% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
